Axogen completes acquisition of BioCircuit Technologies
AXGN•Axogen completed its acquisition of privately held BioCircuit Technologies, adding the NerveTape device for sutureless peripheral nerve repair. BioCircuit is expected to contribute about $6 million in fourth-quarter 2026 revenue and about $34 million in 2027 revenue.
1. Acquisition and outlook
Axogen completed its acquisition of privately held BioCircuit Technologies, adding NerveTape, a device for sutureless peripheral nerve repair. BioCircuit is expected to contribute about $6 million in revenue in the fourth quarter of 2026 and about $34 million in 2027; the 2027 contribution is not included in Axogen’s latest 2026 outlook of at least 24% growth. Axogen reiterated its full-year 2026 gross margin guidance of at least 73% and maintained its expectation to be free cash flow positive for the year.
